Yuandong Tian, who spent more than a decade as a research scientist director inside Meta’s Fundamental AI Research lab, has ...

That brings us to Recursion Pharmaceuticals (RXRX 5.59%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Abstract: The Visualized LL parsing is presented, the algorithm is based on non-left recursive grammar, and in the environment of VC++, it is based on the relation matrix of the grammar, with the help ...

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...